LRRK2 and Parkinson disease: Furthermore, our continuous <i>PD Weigh-In</i> score captured clinical decline in two carriers who subsequently developed PD and correlated strongly with expert ratings (Pearson <i>r</i> = <b>0.77</b>, Spearman ρ = <b>0.79</b>) across the held-out <i>LRRK2</i> test cohort.